Occuity strives for constant and revolutionary innovation. Our ambitious and experienced team are leading the way to tackle with world’s most prevalent chronic diseases.
The potential power of our technology is fascinating, and what better way to get to know our innovative tech than to sit down and have a chat with our founder & CTO, Robin Taylor to discuss how Occuity’s novel patented technology actually works and what exciting products are in the pipeline.
How does it feel to see the company you founded experience so much growth?
It feels fantastic to see what started with Dan and Myself in my garage grow into what Occuity has now become. Just in the last year, we have doubled the size of our team, which in itself just shows how much we are growing and advancing.
The level of interest our vision has generated since we started has been amazing and to have the support from so many investors, both direct and those who invested through our crowdfunding campaign, really shows that the products we have in our pipeline have the potential to improve the lives of millions of people.
What makes the eye uniquely suited to Occuitys technology?
A lot of people think that the eye is simply used to view the world around us however it is so much more. For example, when it comes to chronic diseases such as diabetes and Alzheimer’s, they leave tell-tale markers behind in the form of proteins as the disease progresses. The eye, being an optical system itself has evolved to transmit light. Our technology being optical, non-contact and low power means we are able to safely look into the eye and detect these changes.
How does Occuity’s revolutionary patented technology actually work?
In its simplest form, Occuity’s technology is designed to take highly accurate measurements of some of the structures within the eye – for example, the thickness of the cornea or the level of fluorescence within the eye – to determine changes in the body.
We are able to do this by safely scanning a low power beam of light through the eye and analysing the return signals, with various structures within the eye providing different signals that can then be collected and interpreted by our team.
What makes Occuity technology different from competitors?
I believe that our technology is uniquely capable of being developed into a new generation of non-contact devices for the screening and monitoring of chronic health conditions. These will be pain-free, use no consumables and give immediate results. Furthermore, our technology is compact enough that it can be integrated into handheld devices and, with our strong focus on usability, they are intended to be easy and convenient to use.
Finally, what does Occuity have in the product pipeline?
It has been very busy year at Occuity, not only has our team grown significantly, but we also now have a number of projects happening in parallel. I won't list them all, but our primary focus is PM1 pachymeter, which is getting ready for clinical trials. We are also forging ahead with the development of our non-invasive glucose monitor, of which we have a number of benchtop prototypes that are being used for in-house verification testing. We have also identified a very exciting opportunity for a new product - a handheld, non-contact axial length meter for myopia screening and monitoring.
To learn more about Occuity's cutting edge novel optical technology click here